Jensen Kristian Vestergaard, Frid Maria, Stödberg Tommy, Barbaro Michela, Wedell Anna, Christensen Mette, Bak Mads, Ek Jakob, Madsen Camilla Gøbel, Darin Niklas, Grønborg Sabine
Department of Neonatology Copenhagen University Hospital Copenhagen Denmark.
Department of Paediatrics Ryhov County Hospital Jönköping Sweden.
JIMD Rep. 2019 Sep 30;50(1):1-8. doi: 10.1002/jmd2.12063. eCollection 2019 Nov.
Vitamin B6-responsive epilepsies are a group of genetic disorders including deficiency, deficiency, and others, usually causing neonatal onset seizures resistant to treatment with common antiepileptic drugs. Recently, biallelic mutations in were shown to be a novel cause of vitamin B6-dependent epilepsy with a variable phenotype. The different vitamin B6-responsive epilepsies can be detected and distinguished by their respective biomarkers and genetic analysis. Unfortunately, metabolic biomarkers for early detection and prognosis of deficiency are currently still lacking. Here, we present data from two further patients with vitamin B6-dependent seizures caused by variants in , including a novel missense variant, and compare their genotype and phenotypic presentation to previously described cases. Hyperglycinemia and hyperlactatemia are the most consistently observed biochemical abnormalities in pyridoxal phosphate homeostasis protein (PLPHP) deficient patients and were present in both patients in this report within the first days of life. Lactic acidemia, the neuroradiological, and clinical presentation led to misdiagnosis of a mitochondrial encephalopathy in two previously published cases with an early fatal course. Similarly, on the background of glycine elevation in plasma, glycine encephalopathy was wrongly adopted as diagnosis for a patient in our report. In this regard, lactic acidemia as well as hyperglycinemia appear to be diagnostic pitfalls in patients with vitamin B6-responsive epilepsies, including PLPHP deficiency.
In vitamin B6-responsive epilepsies, including PLPHP deficiency, there are several diagnostic pitfalls, including lactic acidemia as well as hyperglycinemia, highlighting the importance of a pyridoxine trial, and genetic testing.
维生素B6反应性癫痫是一组遗传性疾病,包括[具体缺乏症1]、[具体缺乏症2]等,通常导致新生儿期发作,对常用抗癫痫药物治疗无效。最近,[基因名称]的双等位基因突变被证明是维生素B6依赖性癫痫具有可变表型的新病因。不同的维生素B6反应性癫痫可通过其各自的生物标志物和基因分析进行检测和区分。不幸的是,目前仍缺乏用于早期检测和评估[具体缺乏症]预后的代谢生物标志物。在此,我们展示了另外两名由[基因名称]变体导致的维生素B6依赖性癫痫患者的数据,包括一个新的错义变体,并将他们的基因型和表型表现与先前描述的病例进行比较。高甘氨酸血症和高乳酸血症是磷酸吡哆醛稳态蛋白(PLPHP)缺乏患者中最常观察到的生化异常,本报告中的两名患者在出生后的头几天均出现了这些异常。乳酸血症、神经放射学表现和临床表现导致了两例先前发表的早期致命病例被误诊为线粒体脑病。同样,在血浆甘氨酸升高的背景下本报告中的一名患者被错误地诊断为甘氨酸脑病。在这方面,乳酸血症以及高甘氨酸血症似乎是维生素B6反应性癫痫患者(包括PLPHP缺乏症)的诊断陷阱。
在包括PLPHP缺乏症在内的维生素B6反应性癫痫中,存在几个诊断陷阱,包括乳酸血症以及高甘氨酸血症,这突出了吡哆醇试验和基因检测的重要性。